{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.58","upperLimit":"1.00","value":"0.74"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"0.50","value":"0.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Time of maximum observed serum concentration of Analyte BMS-986016","dispersionType":"Full Range","groups":[{"description":"Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W","id":"OG000","title":"Part A - Flat Dosing (AF)"},{"description":"Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W","id":"OG001","title":"Part A - Age/Weight-based Dosing (AW)"}],"paramType":"MEDIAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Time to Maximum Concentration (Tmax)","type":"PRIMARY","unitOfMeasure":"hour"}